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Cisplatin is widely employed in combating renal cancers. However, a major challenge is the resistance of cisplatin by 
renal cancer cells. Increased miR-222 expression is known to promote this resistance and so ways of downregulating the 
expression of miR-222 is widely sought after as a means of combating the resistance. The study was performed to explore 
the effects of miR-222 on cisplatin resistance of renal cancer cell strains and related mechanisms. The expression of  
miR-222 and Dickkopf-3 (DKK3) was regulated to explore the effects of miR-222 and DKK3 on cisplatin chemotherapy in 
renal cancer cisplatin-resistant cell strains, and to figure out the regulatory relationship between miR-222 and DKK3.  
In renal cancer tissues and cell lines, miR-222 was highly expressed and DKK3 was lowly expressed. Renal cancer 
cisplatin-resistant cells had markedly higher miR-222 expression and lower DKK3 expression than normal renal  
cancer cells, suggesting a potential involvement of miR-222 and DKK3 in the cisplatin resistance in renal cancer cells. 
Down-regulated miR-222 expression led to stronger inhibition of the renal cancer cell growth by cisplatin and markedly 
higher DKK3 expression. Dual-luciferase reporter assay results showed that miR-222 had a targeted inhibition on DKK3. 
Co-transfection of miR-222 mimic and shDKK3, together with the up-regulation of miR-222 and DKK3 expressions, 
resulted in a higher sensitivity of renal cancer cells to cisplatin chemotherapy than the up-regulation of miR-222 expression 
alone. Down-regulated miR-222 expression can remove the inhibition of DKK3 expression and increase the sensitivity of 
renal cancer cells to cisplatin chemotherapy. 
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Accounting for about 3% of all malignant tumors, 
renal cell carcinoma is quite common. In recent years, 
renal clear cell carcinoma has had a yearly stepwise 
increase in its incidence, with annual new cases of 
about 250000 patients and annual deaths of over 
100000 people1,2. 
Despite the great progress in treatment strategies, 
the prognosis of patients using existing treatment 
methods is still disappointing. Chemotherapy 
resistance and metastasis are the main causes of 
deaths from renal cancer. Renal cancer generally 
shows low response to conventional chemotherapy, 
for example, patients with metastatic renal cell 
carcinoma (RCC) often develop resistance against 
anti-angiogenic therapy3. 
Cisplatin is the most widely used and most effective 
chemotherapeutic drug, which, unfortunately, results in 
a general resistance against cisplatin in cancer 
treatment4. MicroRNAs (miRNAs) are a group of  
non-coding RNAs, 19 to 24 nucleotides in length, 
forming a complex biological process regulatory 
network, enjoying an involvement in life activities 
such as tumorigenesis5. 
Recently, there is increasing evidence that miRNAs 
play a crucial role in chemical resistance, but the 
molecular mechanisms by which miRNAs regulate 
drug resistance in various cancers remain unclear6,7. 
miR-222, located in Xp11.3, is down-regulated in 
multiple tumors, including renal cancer8,9. MiR-222 is 
a promising predicting marker for the treatment of 
metastatic renal cell carcinoma with sunitinib, and it 
can affect the sensitivity of renal cancer cells to 
sunitinib treatment by a target binding to the vascular 
endothelial growth factor receptor. Gu et al.10 
discovered the involvement of miR-222 in tamoxifen 
resistance of breast cancer cells. 
The above-listed studies believe miR-222 is closely 
related to tumor cell resistance, but little is reported 
on the relationship between miR-222 and cisplatin 
resistance in renal cancer cells. This study explored 
the effects of miR-222 on cisplatin resistance of renal 
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cancer cell strains and related mechanisms, hoping to 
find out new therapeutic targets for clinical treatment 
of renal cancer. 
 
Materials and Methods 
Research subjects and source of patients 
Nineteen samples of renal cancer tissues and 19 
samples of corresponding tumor-adjacent tissues were 
collected from renal cancer patients (aged from 45 to 
60 years) who were admitted to our hospital (Linyi 
People's Hospital, Linyi, Shandong, 276000, China) 
from March 2017 to May 2018. Inclusion criteria 
included patients with complete medical records and 
diagnosed with renal cancer by postoperative 
pathological diagnosis. Exclusion criteria included 
patients with metastatic renal cancer or previous 
presence of other tumors; pregnant or lactating 
women. This study was approved by the ethics 
committee of our hospital (Linyi People's Hospital, 
Linyi, Shandong, 276000, China) and awarded ethical 
committee number (LPH/PH/18/056). All patients and 
their families gave informed consent through the 
telephone or letter. 
 
Source of cells 
Human renal epithelial cells 293F and human renal 
cancer cells A498, SN12C, A704, OS-RC-2, 769-P  
were purchased from BeNa Culture Collection (cell 
numbers: BNCC340697, BNCC338630, BNCC341858, 
BNCC342393, BNCC100729, BNCC101643). Normal 
cell culture medium was composed of 90% high glucose 
DMEM (Thermo Fisher Scientific Inc., item No. 
11965084) + 10% fetal bovine serum (Thermo Fisher 
Scientific Inc., item No. 16250086). Renal cancer cell 
strain medium was composed of 90% RPMI-1640 
medium (Thermo Fisher Scientific Inc., item No. 
61870044) + 10% fetal bovine serum + penicillin at a 
concentration of 100 U/mL and streptomycin at a 
concentration of 100 μg/mL. Cells were incubated in a 
constant temperature incubator at 37°C under 5% CO2. 
The cells were passaged for 2-3 generations before use. 
 
Construction of cell strains with drug resistance 
Drug resistance of cells was induced by pulse 
therapy combined with continuous stepwise exposure 
to the drug. Logarithmically growing renal cancer 
cells were resuspended and routinely seeded in  
96-well plates (3000 cells per well), and cultured in 
an incubator with 5% CO2 at 37°C for 6-12 h. Then 
various concentrations of cisplatin (0.001, 0.01, 0.1, 
1, and 10 μg/mL) were added to the culture plates,  
5 parallel wells for each concentration. After 48 h of 
culture, MTT assay was used to determine the cell 
growth inhibition rate and the IC50 value was 
calculated. Renal cancer cells were re-inoculated, and 
the cisplatin resistance of renal cancer cells was 
induced with an initial concentration of 10% of IC50 
value. The drug concentration was increased at the 
time of stable cell growth, finally the stable survive of 
cells was achieved at a cisplatin concentration of  
0.5 μg/mL. 
 
Construction and transfection of the expression vector 
miR-122-mimic, miR-122-inhibitor, miR negative 
control (miR-NC), and targeted Dickkopf-3 (DKK3) 
RNA (shDKK3) were constructed by Shanghai 
GenePharma Co., Ltd. The miR-NC group, miR-222 
mimic group, miR-222 inhibitor group, and  
co-transfection group (miR-596 mimic + shDKK3) 
were set. The renal cancer resistant cell strains were 
digested by trypsin 24 h before the transfection. The 
transfection of expression vector was performed when 
the cells reached 80% confluence in strict accordance 
with the kit instructions. The incubator was cultured at 
37°C with 5% CO2 for 48 h, and the medium was 
changed every 6 h. Transfection results were detected  
by qRT-PCR and Western blot methods. The 
LipofectamineTM 2000 Transfection Kit was purchased 
from Invitrogen, USA (item number No. 35050). 
 
qRT-PCR detection 
This was performed as described by Crookenden et al. 
with little modifications11. The total RNA was 
extracted from collected cells using a TRIzol kit 
(Invitrogen, USA, 15590618). The purity, concentration, 
and integrity of total RNA were measured by ultraviolet 
spectrophotometry and agarose gel electrophoresis. The 
reverse transcription was conducted according to the 
cDNA synthesis kit manual. The amplification system 
of miR-222 was as follows: 1 μL of cDNA, 0.4 μL of 
forward primer, 0.4 μL of reverse primer, 10 μL of 
2×TransTaq® Tip Green qPCR SuperMix , 0.4 μL of 
Passive Reference Dye (50×), and enough ddH2O to 
complement the system to 20 μL. PCR amplification 
conditions: 40 cycles of pre-denaturation at 94℃ for 
30 sec, denaturation at 94°C for 5 sec, annealing and 
extension at 60°C for 30 sec. Three replicate wells 
were set for each sample, and the experiment was 
carried out for 3 times. U6 was used as the internal 
reference of miRNA, GAPDH was the internal 
reference of mRNA. The data were analyzed using  
2-△△ct. The qRT-PCR and reverse transcription kits 
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were purchased from TransGen Biotech, Beijing, 
China (item numbers: AQ201-01, AQ202-01). The 
primer sequences were shown in (Table 1). 
 
Western Blot analysis 
Western blot analysis was performed as described 
by Zhaowei et al. with slight modification12. The total 
protein was extracted by RIPA lysis method, and its 
concentration was determined by BCA method. Then 
the protein concentration was adjusted to 4 μg/μL and 
the protein was separated by 12% polyacrylamide gel 
electrophoresis. The initial voltage was 90 V, and 
then the voltage was increased to 120 V to move the 
sample to the appropriate position of the separation 
gel. After the accomplishment of electrophoresis, the 
membrane was transferred (100 V constant pressure 
for 100 min and 37°C for 60 min). The transferred 
membrane was then blocked in 5% skim milk and the 
immune reaction was carried out. The membrane was 
incubated with the primary antibody (1:1000) 
overnight at 4°C. On the next day, the membrane was 
washed for three times with PBS (5 min for each 
time) and then incubated with secondary antibody 
(1:1000) for 1 h at room temperature (25°C). 
Following that, color development and fixation were 
performed using ECL luminescence reagent. Statistical 
analysis was performed on the band after film  
scanning using Quantity One software. Protein relative 
expression level = gray value of band/gray value of 
internal reference. RIPA kit, BCA protein kit, ECL 
luminescence kit, and trypsin were purchased from 
Thermo ScientificTM (item number: 89901, 23250, 
35055, 90058). The anti-rabbit DKK3 monoclonal 
antibody and goat anti-rabbit IgG secondary antibody 
was purchased from the Abcam (the United States, 
item number: ab38594, ab6721). 
 
Dual-luciferase reporter assay 
Dual luciferase reporter gene assay was performed 
as described by Ting et al. with adjustments13. Human 
embryonic kidney cell 293T was purchased from BeNa 
Culture Collection (cell number: BNCC100530). 
Logarithmically growing cells were harvested and 
transfected with pmirGLO-DKK3-3'UTR wild type 
(Wt), pmirGLO-DKK3-3'UTR mutant type (Mut), 
miR-222-mimics, and miR-NC. The fluorescence 
intensity was measured 48 h after the transfection using 
a dual-luciferase assay system (CytoFLE S flow 
cytometer, Beckman, the USA). The sequences were 
designed by Thermo Fisher Scientific (China) Co., Ltd. 
 
Cell proliferation assay in vitro 
Cell proliferation assay using MTT was performed as 
described by Tazehkand et al.14. The cells were harvested 
24 h after the transfection and seeded in 96-well plates at 
a density of 3*104 cells/well, and incubated at 37°C for 
48 h. Next, 20 μL of MTT solution (5 μg/mL) was added 
and the plates were continuously inoculated at 37°C for  
4 h. Then, 150 μL of dimethyl sulfoxide was added to 
each well. Finally, the OD value of each group was 
measured using a microplate reader (Shanghai Flash 
Spectrum Biotechnology Co., Ltd.) at 490 nm. MTT 
assay kit was purchased from Beijing Fangcheng Jiahong 
Technology Co., Ltd. 
 
Statistical analysis 
Statistical analysis was performed sing SPSS19.0 (Asia 
Analytics Formerly SPSS China). The measurement data 
were expressed as Mean ± Standard deviation (Mean ± 
SD). The comparison between the two groups was 
performed by independent sample t-test, and the 
comparison between multiple groups was analyzed by 
one-way ANOVA and LSD post hoc test. Pearson 
correlation was used to analyze the correlation between 
miR-222 and DKK3 expression. A statistical difference 
was recognized when P <0.05. 
 
Results 
Expression levels of miR-222 and DKK3 in renal cancer 
tissues 
Renal cancer tissues had notably higher miR-222 
expression and notably lower DKK3 expression than 
adjacent normal tissues (both P <0.05). Pearson analysis 
indicated a negative correlation between miR-222 and 
DKK3 expressions (P <0.05). (Fig. 1) 
 
Expression levels of miR-222 and DKK3 in renal cancer cell 
strains 
miR-222 expression was significantly higher in 
renal cancer cells A498, SN12C, A704, OS-RC-2, and  
769-P than in renal epithelial cells 293F (P <0.05), 
while DKK3 was significantly lower than in 293F 
cells (P <0.05) (Fig. 2). 
 
Construction of cell strains with drug resistance 
The growth inhibition rates of renal cancer cell 
strains A498 and OS-RC-2 exposed to different 
Table 1 — Primer sequences 
 forward primer reverse primer 
miR-222 5-GTTCGTGGGAG 
CTACATCTGGC-3 
5-GCAGGGTCC 
GAGGTATTC-3 
U6 5-GCGCGTCGT 
GAAGCGTTC-3 
5-GTGCAGG 
GTCCGAGGT-3 
GAPDH 5-TGCACCACCA 
ACTGCTTAG-3 
5-GATGCAGG 
GATGATGTTC-3 
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concentrations of cisplatin are shown in (Fig. 3A & B). 
According to the linear regression equation, the IC50 
of A498 and OS-RC-2 were 0.1077 μg/mL and 
0.0733 μg/mL, respectively. Cisplatin resistance was 
induced by continuous stepwise exposure to cisplatin 
combined with pulse therapy in vitro. The growth 
inhibition rates of cisplatin-resistant cells A498 
(A498/DDP) and OS-RC-2 (OS-RC-2/DDP) exposed 
to different concentrations of cisplatin are shown  
in (Fig. 3C & D). The IC50 of A498 and OS-RC-2  
were 9.5170 μg/mL and 13.1129μg/mL, respectively, 
suggesting a success in constructing cisplatin-resistant 
cell strains. 
Expression levels of miR-222 and DKK3 in renal cancer cell 
strains with drug-resistance 
A498/DDP and OS-RC-2/DDP cells had notably 
higher miR-222 level and lower DKK3 level than 
A498 and OS-RC-2 cells (both P <0.05) (Fig. 4). 
 
Effects of down-regulated miR-222 on cisplatin chemotherapy 
in renal cancer cell strains 
After transfection with miR-222 inhibitor, the 
expression levels of miR-222 in A498/DDP and  
OS-RC-2/DDP cells in the miR-222 inhibitor group 
were significantly lower than those in the miR-NC 
group (P <0.05). After 48 h of culture in cisplatin at a 
concentration of IC50 for cisplatin-resistant cell 
strains, the growth inhibition rates of A498/DDP and 
OS-RC-2/DDP cells in the miR-222 inhibitor group 
were significantly higher than those in the miR-NC 
group (P <0.05) (Fig. 5). 
 
Effects of down-regulated miR-222 on the DKK3 expression 
After transfection with miR-222 inhibitor, the 
expression levels of DKK3 in A498/DDP and  
OS-RC-2/DDP cells in the miR-222 inhibitor group 
were significantly higher than those in miR-NC group 
(P <0.05). The dual-luciferase report assay revealed a 
targeted regulation on DKK3 by miR-222 (P <0.05) 
(Fig. 6). 
 
 
Fig. 1 — Expression levels of miR-222 and DKK3 in renal cancer 
tissues (A) Expression level of miR-222 in renal cancer tissues; 
(B) Expression level of DKK3 in renal cancer tissues; and 
(C) Correlation analysis between miR-222 and DKK3 expressions 
in renal cancer tissues 
 
 
Fig. 2 — Expression levels of miR-222 and DKK3 in renal cancer 
cell strains (A) Expression level of miR-222 in renal cancer cell 
strains; and (B) Expression level of DKK3 in renal cancer strains 
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Rescue experiment 
After co-transfection with miR-222 mimic + shDKK3, 
the expression levels of DKK3 in A498/DDP and  
OS-RC-2/DDP cells in the co-transfection group  
were significantly higher than those in miR-222 
mimic group (P <0.05) while no significant 
difference was detect in the expression of miR-222 
between the two groups (P >0.05). After 48 h  
of culture in cisplatin at a concentration of IC50  
for cisplatin-resistant cell strains, the growth 
inhibition rates of A498/DDP and OS-RC-2/DDP 
cells in the miR-222 mimic group were significantly 
lower than that in the co-transfection group (P <0.05) 
(Fig. 7). 
 
 
Fig. 3 — Construction of cell strains with drug resistance 
(A) Growth inhibition of renal cell strain A498 by different 
concentrations of cisplatin; (B) Growth inhibition of renal cell 
strain OS-RC-2 by different concentrations of cisplatin; 
(C) Growth inhibition of renal cell A498/DDP by different 
concentrations of cisplatin; and (D) Growth inhibition of renal cell 
OS-RC-2/DDP by different concentrations of cisplatin 
 
 
 
Fig. 4 — Expression levels of miR-222 and DKK3 in renal cancer 
cell strains with drug-resistance (A) miR-222 expression in 
A498/DDP and OS-RC-2/DDP cells; and (B) DKK3 expression in 
A498/DDP and OS-RC-2/DDP cells 
 
Fig. 5 — Effects of down-regulated miR-222 on cisplatin 
chemotherapy in renal can cell strains (A) Results of transfection 
with miR-222 inhibitor; and (B) Effects of down-regulated 
miR-222 on cisplatin chemotherapy in A498/DDP and OS-RC-
2/DDP cells 
 
 
 
Fig. 6 — Certification analysis on the relationship between miR-
222 and DKK3 (A) Effects of down-regulated miR-222 on the 
DKK3 expression; and (B) Dual-luciferase reporter assay 
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Discussion 
DKK3 is a soluble Wnt inhibitor that binds to  
low-density lipoprotein receptor-associated protein 
5/6 and disrupts the stability of cellular plasma  
β-catenin to play a role in molecular therapy of 
tumors. Studies by Mohammadpour et al.15 have 
reported the down-regulation of DKK3 in various 
tumors including renal cancer. In recent years, DKK3 
has been found to be closely related to tumor cell 
resistance, but whether it has an influence on of renal 
cancer cell resistance is not sure. miR-222 has also 
been reported to be associated with a variety of tumor 
resistance. So far, it has not been figured out whether 
miR-222 is involved in tumor resistance by regulating 
DKKS. The present study revealed that down-regulated 
miR-222 expression can remove the inhibition of DKK3 
expression and increase the sensitivity of renal cancer 
cells to cisplatin chemotherapy. 
In this study, miR-222 was highly expressed in renal 
cancer tissues and cell lines and DKK3 was lowly 
expressed in them, besides, renal cancer cisplatin-
resistant cells had higher miR-222 expression and 
lower DKK3 expression than ordinary renal cancer 
cells, suggesting that miR-222 and DKK3 may be 
associated with cisplatin resistance in renal cancer 
cells. The down-regulation of miR-222 expression 
resulted in stronger inhibition of the renal cancer cell 
growth by cisplatin and markedly up-regulation of 
DKK3 expression. Dual-luciferase reporter assay 
results showed that miR-222 could enhance the 
fluorescence intensity of DKKS, indicating a targeted 
inhibition on DKK3 by miR-222.  
The rescue experiment demonstrated that the up-
regulation of miR-222 and DKK3 expressions 
combined with the co-transfection of miR-222 mimic 
and shDKK3 resulted in a higher sensitivity of renal 
cancer cells to cisplatin chemotherapy than the  
up-regulation of miR-222 expression alone did, 
indicating that DKK3 is a target for miR-222 to 
regulate cisplatin resistance in renal cancer cells. 
Recently, some studies have unveiled the role of 
miR-222 in affecting tumor cell resistance and its 
mechanism. Yu et al.16 reported that exosomes of 
adriamycin-resistant breast cancer cells can transfer 
miR-222 to transmit drug resistance. Shen et al.17 
stated that miR-222 can enhance the resistance of 
breast cancer cells to doxorubicin by regulating the 
PTEN/Akt/FOXO1 pathway. In addition to breast 
cancer, miR-222 can also modulate the sensitivity of 
multiple tumors such as multiple myeloma, glioma18, 
bladder cancer19 to chemotherapeutic drugs, but no 
studies have reported the effects of miR-222 on the 
resistance of renal cancer cells so far.  
According to the above-listed studies, the induction 
of tumor resistance by miR-222 is very likely to be 
ubiquitous, which means miR-222's influence on the 
resistance of renal cancer cells is also possible. 
Fortunately, this study confirmed this possibility. Dkk 
3 is a tumor suppressor that performs it functions by 
regulating Wnt signaling pathway. Also, miR-222 can 
target DKK2 to activate Wnt signaling pathway to 
promote glioma development. As a member of the 
DKK family, DKK2 has similar amino acid sequences 
to DKK3, but unlike DKK3, DKK2 is an activator of 
the Wnt signaling pathway20. Studies by Wang et al.20 
reported that miR-221 was discovered to target DKK2 
expression and mediate the drug-resistance of 
esophageal adenocarcinoma. miR-221 and miR-222 
have the same seed sequences, which means that 
DKK2 may be another target of miR-222 to affect 
tumor cell resistance. Such facts also indicate that 
miR-221, miR-222, DKK2, and DKK3 may all 
participate in tumor cell resistance by forming a 
complex regulatory network, but this requires further 
research and validation. 
This study marks the first to uncover the 
involvement of miR-222 in cisplatin resistance in renal 
cancer cells through its targeted regulation of DKK3, 
not verified by other studies. So, we hope to see more 
similar studies in the future to provide validation for 
the results and conclusions of this study. This study is 
subject to certain shortcomings. For example, despite 
the large number of renal cancer resistant cell strains, 
the in-vitro cell experiment in this study failed to 
simulate the complex tumor microenvironment of the 
body, waiting to be verified by in vivo experiments. In 
 
Fig. 7 — Rescue experiment (A) Effects of co-transfection on the 
DKK3 expression; (B) Effects of co-transfection on the miR-222 
expression; and (C) Effects of co-transfection on cisplatin 
chemotherapy in A498/DDP and OS-RC-2/DDP cells 
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addition, the clinical value of miR-222 and DKK3 in 
the diagnosis and prognosis evaluation of renal cancer 
is rarely studied. We will include this part in our study 
purpose in future researches. 
 
Conclusion 
In summary, miR-222 regulates the drug-resistance of 
renal cancer cells by targeting DKKS. Down-regulated 
miR-222 expression can remove the inhibition of DKK3 
expression and increase the sensitivity of renal cancer 
cells to cisplatin chemotherapy, suggesting the 
possibility of miR-222 to work as a potential target for 
clinical treatment of renal cancer in the future. 
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